cancer sequencing
The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.
Illumina, Geneseeq Technology to Collaborate on IVD Cancer Testing Kits in China
The deal to create a comprehensive genomic profiling test for Illumina's NextSeq 550Dx comes months after the instrument received regulatory approval in China.
Natera Revenues Grow 35 Percent in Q4
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
NantHealth Q4 Revenues Flat From Year Ago
The firm posted total software-related revenues of $18.6 million, up 1 percent from $18.4 million in Q4 2019.
The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.
Nov 5, 2020
NantHealth Q3 Revenues Tick Up Slightly
Sep 11, 2020
Natera Prices $250M Public Stock Offering
Aug 6, 2020
NantHealth Q2 Revenues Decline 12 Percent
Jul 29, 2020
Sema4 Raises $121M in Series C Financing Round
May 4, 2020